Fist line chemotherapy in advanced ovarian cancer: a comparison of three therapeutic regimes.
The first line polichemotherapeutic regimens are compared (intracavitary Cyclophosphamide + CMF, ACy and PEC) in 47 patients with advanced ovarian carcinoma. The response was 56.4% for Ex-CMF (CR 39.1%), 76.8% for ACy (CR 61.5%) and 81.8% for PEC (CR 63.6%). The three-year survival was 39.1% with Ex-CMF, 53.8% with ACy and 72.7% (follow-up not yet completed) for PEC. Toxicity was modest in all the three therapeutic regimens.